Prevduo, a Neostigmine-Glycopyrrolate Combo Product, Now Available

Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) has been made available by Endo for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (eg, bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration.
Prevduo contains a fixed-dose combination of neostigmine, a cholinesterase inhibitor and glycopyrrolate, an antimuscarinic agent. Both drugs have been previously approved as single agent products; the new combination removes the need for 2 syringe preparations and administrations.
“This is the latest way we’re addressing operational and clinical challenges in order to support patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “With 2 medications in one ready-to-use syringe, Prevduo reduces complexity and increases efficiency for hospitals and health care providers.”
Prevduo is supplied as a solution containing 3mg/3mL of neostigmine methylsulfate and 0.6mg/3mL of glycopyrrolate (1mg/mL of neostigmine methylsulfate and 0.2mg/mL of glycopyrrolate) in a single-dose 3mL prefilled syringe. The product will be distributed in the US by Slayback Pharma LLC.